NDAINJECTIONINJECTABLE
Approved
Dec 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
CORVERT (ibutilide fumarate) by Pfizer is mechanism of action: corvert injection prolongs action potential duration in isolated adult cardiac myocytes and increases both atrial and ventricular refractoriness in vivo , ie, class iii electrophysiologic effects. First approved in 1995.
Drug data last refreshed 13h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CORVERT (ibutilide fumarate) is an intravenous class III antiarrhythmic agent approved in 1995 for rapid conversion of atrial fibrillation and atrial flutter to normal sinus rhythm. It works by prolonging action potential duration and refractoriness through activation of a slow inward sodium current, a unique mechanism among class III agents. The drug is administered as a short IV infusion in acute care settings.
LOE Approaching
Product is in late-stage lifecycle with approaching loss of exclusivity and modest competitive pressure (30%), indicating a mature, stable-to-declining commercial profile with reduced team expansion.
Mechanism of Action
Mechanism of Action: CORVERT Injection prolongs action potential duration in isolated adult cardiac myocytes and increases both atrial and ventricular refractoriness in vivo , ie, class III electrophysiologic effects. Voltage clamp studies indicate that CORVERT, at nanomolar concentrations, delays…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CORVERT represents a niche, mature franchise with limited career growth but deep specialization in acute arrhythmia management and hospital-based care. Professionals joining this product should expect stable but declining commercial opportunities as LOE approaches and generics enter.
Brand Manager
Worked on CORVERT at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.